Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,730.00
Bid: 1,730.00
Ask: 1,730.50
Change: 1.50 (0.09%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Markets up on positive company news

Wed, 22nd Oct 2014 17:04

The London market closed in positive territory for the second time this week as traders weary of negative economic news took heart from upbeat corporate results.The FTSE 100 Index ended the session 27.4 points ahead at 6399.73 as drug group GlaxoSmithKline pleased investors with news of higher earnings per share despite US and European weakness. It also said it was launching a restructuring drive to cut costs and streamline its business. Glaxo's shares bounced 35p to 1,377p.On the economic front, minutes from the Bank of England's most recent meeting showed no further urge by members to start thinking about raising interest rates, with the split between 'doves' and 'hawks' remaining unchanged from the last meeting at 7-2.Capital Spreads dealer William Nicholls said: "Given the volatility in financial markets of late, there is unlikely to be any move on this sentiment since the meeting, if anything they are likely to become more accommodative."Investors took cover in car insurers after the Automobile Association (AA) said price declines in the industry were over.Admiral Group ticked up 42p to 1285p and Direct Line advanced 8.5p to 279.6p. But the AA itself reversed 2.25p or 0.72% to 310.25p.Supermarkets were on the slide after Waitrose said the business model of the Big Four retailers was outdated and insolvency group Begbies Traynor forecast a bad Christmas unless they make changes.Sainsbury was 8.4p off at 241.6p, Morrisons backtracked 4.2p to 157.9p and Tesco, which releases first-half results tomorrow, fell 2.9p to 183p.British American Tobacco wafted 91.5p lower to 3375p after warning of a foreign exchange hit and weak European markets.Fashion house Supergroup faded 54p to 975p as worries about the impact on sales of warm autumn weather eclipsed news that former Co-op boss Euan Sutherland was to become its new chief executive.Market MoverstechMARK 2,674.09 +1.20%FTSE 100 6,399.73 +0.43%FTSE 250 15,170.06 +0.97%FTSE 100 - RisersAdmiral Group (ADM) 1,285.00p +3.38%Direct Line Insurance Group (DLG) 279.60p +3.14%GlaxoSmithKline (GSK) 1,377.00p +2.61%ARM Holdings (ARM) 827.00p +2.61%Whitbread (WTB) 4,298.00p +2.33%Old Mutual (OML) 181.90p +2.19%Babcock International Group (BAB) 1,079.00p +2.18%Smith & Nephew (SN.) 982.50p +2.13%Dixons Carphone (DC.) 374.30p +2.10%Royal Mail (RMG) 448.70p +1.98%FTSE 100 - FallersSainsbury (J) (SBRY) 241.60p -3.36%Fresnillo (FRES) 784.00p -3.03%British American Tobacco (BATS) 3,375.00p -2.64%Morrison (Wm) Supermarkets (MRW) 157.90p -2.59%Randgold Resources Ltd. (RRS) 4,170.00p -2.55%Rio Tinto (RIO) 3,089.50p -1.61%Tesco (TSCO) 183.00p -1.56%BHP Billiton (BLT) 1,664.50p -1.48%Weir Group (WEIR) 2,258.00p -1.44%Anglo American (AAL) 1,356.50p -1.31%FTSE 250 - RisersPace (PIC) 335.90p +9.20%Zoopla Property Group (WI) (ZPLA) 214.00p +6.47%esure Group (ESUR) 235.00p +5.90%Croda International (CRDA) 2,215.00p +5.83%Laird (LRD) 310.00p +5.19%Playtech (PTEC) 737.50p +5.06%International Personal Finance (IPF) 480.00p +5.03%Keller Group (KLR) 797.50p +4.93%Ophir Energy (OPHR) 209.50p +4.23%Foxtons Group (FOXT) 205.30p +4.21%FTSE 250 - FallersSupergroup (SGP) 975.00p -5.25%Lonmin (LMI) 181.90p -2.83%AO World (AO.) 173.00p -2.54%Cairn Energy (CNE) 157.40p -2.36%Senior (SNR) 268.90p -2.36%Balfour Beatty (BBY) 161.80p -2.35%EnQuest (ENQ) 74.85p -1.84%Entertainment One Limited (ETO) 303.50p -1.78%African Barrick Gold (ABG) 195.00p -1.71%Poundland Group (PLND) 316.50p -1.71%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.